Acer Drug Patent Portfolio
Acer owns 1 orange book drug protected by 3 US patents Given below is the list of Acer's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11154521 | Palatable compositions including sodium phenylbutyrate and uses thereof | 17 Oct, 2036 | Active |
| US11202767 | Methods of treating urea cycle disorders and maple syrup urine disease | 17 Oct, 2036 | Active |
| US11433041 | Palatable compositions including sodium phenylbutyrate and uses thereof | 17 Oct, 2036 | Active |
Latest Legal Activities on Acer's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acer.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2026 | US11433041 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 13 Aug, 2025 | US11433041 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Jun, 2025 | US11202767 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Apr, 2025 | US11154521 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11154521 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11202767 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Apr, 2024 | US11433041 |
|
Email Notification
Critical
| 02 Apr, 2024 | US11433041 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 06 Sep, 2022 | US11433041 |
|
Recordation of Patent Grant Mailed
Critical
| 06 Sep, 2022 | US11433041 |
|
Email Notification
Critical
| 18 Aug, 2022 | US11433041 |
|
Issue Notification Mailed
Critical
| 17 Aug, 2022 | US11433041 |
|
Application Is Considered Ready for Issue
Critical
| 04 Aug, 2022 | US11433041 |
| Dispatch to FDC | 04 Aug, 2022 | US11433041 |
|
Issue Fee Payment Received
Critical
| 26 Jul, 2022 | US11433041 |
Acer's Family Patents
Clinical Trials
Recent Clinical Trials by Acer:
Acer Drug List
Given below is the complete list of Acer's drugs and the patents protecting them.
1. Olpruva
Olpruva is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11154521 | Palatable compositions including sodium phenylbutyrate and uses thereof |
17 Oct, 2036
(10 years from now)
| Active |
| US11202767 | Methods of treating urea cycle disorders and maple syrup urine disease |
17 Oct, 2036
(10 years from now)
| Active |
| US11433041 | Palatable compositions including sodium phenylbutyrate and uses thereof |
17 Oct, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olpruva's drug page